Top 10 Emerging Pharmaceutical Companies in Europe in 2021 by Revenues

Ipsen SA, Jazz Pharmaceuticals Plc, Endo International Plc, H. Lundbeck AS, and Gedeon Richter Plc are the 5 emerging pharmaceutical companies in Europe in 2021 by revenue. Cumulatively, the top 10 emerging pharmaceutical companies in Europe generated revenue of $20,415 million, the highest revenue was generated by Ipsen SA ($3,546 million), followed by Jazz Pharmaceuticals Plc ($3,094 million) and Endo International Plc ($2,993 million), while CRISPR Therapeutics AG ($915 million) stood the lowest. France-based Ipsen SA is one of the emerging pharmaceutical companies in Europe in 2021 by revenue. It is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company distributes products worldwide, with major markets including Europe; North America; Asia, Latin America, and the Middle East, among others with 5,744 employees. Ireland-based Jazz Pharmaceuticals Plc is one of the top emerging companies in Europe in 2021 by revenue. It is a specialty biopharmaceutical company that identifies, develops, and commercializes medicines with a focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. It employs 3,200 people.